CLINICAL TRIAL SUMMARY

MDACC Study No:SWOG C80405 (clinicaltrials.gov NCT No: NCT00265850)
Title:A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Principal Investigator:Cathy Eng
Treatment Agent:5-FU; Bevacizumab; Cetuximab; Irinotecan; Leucovorin; Oxaliplatin
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the effectiveness of 2
drug combinations for treating patients with advanced colorectal cancer who do
not have K-ras mutations in their tumor tissue: cetuximab plus combination
chemotherapy, and bevacizumab plus combination chemotherapy. The safety of
these 2 combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Colorectal
Phase of Study:Phase III
Treatment Agents:5-FU
Bevacizumab
Cetuximab
Irinotecan
Leucovorin
Oxaliplatin
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:Hospitalization is not required.
Supported By:N/A
Return Visit:ARM A - Every 2 weeks
ARM B & C - Weekly
Home Care:All treatment must be given at M. D. Anderson


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cathy Eng
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults